Development of a Strategic Method for Prevention of Side Effects of Oral Anticancer Agents to Improve Life Prognosis and Quality of Life of Ovarian Cancer Patients

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K07178
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47060:Clinical pharmacy-related
• Research Institution: Gifu Pharmaceutical University
• Principal Investigator: Iihara Hirotoshi 岐阜薬科大学, 薬学部, 研究員 (40775095)
• Co-Investigator(Kenkyū-buntansha): 林 秀樹 岐阜薬科大学, 薬学部, 教授 (00419665) ; 鈴木 昭夫 岐阜大学, 医学部附属病院, 准教授 (80775148) ; 安部 正和 静岡県立静岡がんセンター(研究所), その他部局等, 研究員 (90644063)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: PARP阻害剤 / 悪心 / 嘔吐 / CINV

Outline of Final Research Achievements

A multicenter observational study of chemotherapy-induced nausea and vomiting in patients taking PARP inhibitors was initiated on January 31, 2020, with a target enrollment of 234 patients. A total of 134 patients were enrolled by March 31, 2023. Enrollment was stopped after 134 patients due to lower than expected enrollment for the planned number of years. The observation period for the enrolled cases has been completed and data cleaning is underway. Once data cleaning is complete, statistical analysis will be performed and results will be reported.

Free Research Field

医療系薬学

Academic Significance and Societal Importance of the Research Achievements

本研究の結果は、PARP阻害剤内服患者における化学療法に伴う悪心・嘔吐の管理に関する貴重な情報を提供することが期待される。これにより、悪心・嘔吐の予防や対処方法の改善に寄与することができると考える。